Kun Liu

Kun (Kate) Liu 刘坤 is a seasoned professional in medical safety and pharmacovigilance, currently serving as the Director of Medical Safety and Pharmacovigilance at BioNTech SE since April 2022. Previous experience includes roles as Global Safety Scientist and Associate Director in Medical Affairs at Grünenthal Group, along with serving as Scientific Affairs Manager at Becton Dickinson, where responsibilities included leading a scientific affairs team and designing clinical studies. Additional experience encompasses positions at Genzyme, Novartis Institutes for BioMedical Research, University of Basel, and No.2 Affiliated Hospital of China Medical University. Educational qualifications include an MBA from ESMT Berlin, a Ph.D. in Biomedical Sciences from the University of Basel, an MSc in Physiology from the National University of Singapore, and an M.D. equivalent from China Medical University.